Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Feldmann

Showing results (31-40 of 157) with videos related to

Pageof 16
Sort By:
Current Opinion in Pharmacology|July 14, 2007
Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseasesRichard O Williams, Ewa Paleolog, Marc Feldmann
The International Journal of Biochemistry & Cell Biology|February 13, 2010
Directed issue: novel concepts in inflammationDerek W Gilroy, Marc Feldmann, Karim Dabbagh
Current Opinion in Biotechnology|November 25, 2004
Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseasesPeter C Taylor, Richard O Williams, Marc Feldmann
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2014
Reply: To PMID 23784528Emily M Schmidt, Marc Feldmann, A Allart Stoop
European Journal of Immunology|August 6, 2009
RelB/p50 regulates CCL19 production, but fails to promote human DC maturationChiara Gasparini, Brian M J Foxwell, Marc Feldmann
Microbiology Spectrum|October 12, 2016
Anti-TNF TherapyIrina Udalova, Claudia Monaco, Jagdeep Nanchahal, et al.
International Immunology|November 21, 2014
Anti-TNF therapy: past, present and futureClaudia Monaco, Jagdeep Nanchahal, Peter Taylor, et al.
Arthritis Research & Therapy|July 24, 2012
Gene expression profiling and functional analysis of angiogenic markers in murine collagen-induced arthritisYvonne Raatz, Saleh Ibrahim, Marc Feldmann, et al.
Lancet (London, England)|January 3, 2026
If vaccines falter, broad-spectrum antivirals provide a global shieldRaymond A Dwek, Marc Feldmann, Constantina Fotinou, et al.
Frontiers in Bioscience : a Journal and Virtual Library|June 23, 2005
The toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritisEvangelos Andreakos, Sandra Sacre, Brian M Foxwell, et al.
Pageof 16

Showing results (31-40 of 157) with videos related to

Sort By:
Pageof 16
Current Opinion in Pharmacology|July 14, 2007
Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseasesRichard O Williams, Ewa Paleolog, Marc Feldmann
The International Journal of Biochemistry & Cell Biology|February 13, 2010
Directed issue: novel concepts in inflammationDerek W Gilroy, Marc Feldmann, Karim Dabbagh
Current Opinion in Biotechnology|November 25, 2004
Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseasesPeter C Taylor, Richard O Williams, Marc Feldmann
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2014
Reply: To PMID 23784528Emily M Schmidt, Marc Feldmann, A Allart Stoop
European Journal of Immunology|August 6, 2009
RelB/p50 regulates CCL19 production, but fails to promote human DC maturationChiara Gasparini, Brian M J Foxwell, Marc Feldmann
Microbiology Spectrum|October 12, 2016
Anti-TNF TherapyIrina Udalova, Claudia Monaco, Jagdeep Nanchahal, et al.
International Immunology|November 21, 2014
Anti-TNF therapy: past, present and futureClaudia Monaco, Jagdeep Nanchahal, Peter Taylor, et al.
Arthritis Research & Therapy|July 24, 2012
Gene expression profiling and functional analysis of angiogenic markers in murine collagen-induced arthritisYvonne Raatz, Saleh Ibrahim, Marc Feldmann, et al.
Lancet (London, England)|January 3, 2026
If vaccines falter, broad-spectrum antivirals provide a global shieldRaymond A Dwek, Marc Feldmann, Constantina Fotinou, et al.
Frontiers in Bioscience : a Journal and Virtual Library|June 23, 2005
The toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritisEvangelos Andreakos, Sandra Sacre, Brian M Foxwell, et al.
Pageof 16